Form 4: Director Paula A. Johnson Receives JNJ Deferred Shares
Director Compensation Disclosure
Johnson & Johnson Director Paula A. Johnson acquired 975 deferred share units as part of the company's director compensation plan.
Summary
- Director Paula A. Johnson was granted 975 Deferred Share Units (DSUs) on April 23, 2026.
- These units are acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors.
- The DSUs will be settled in cash upon the termination of the director's service.
- Following this transaction, the director's total beneficial ownership increased to 5,359.3973 units.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine disclosure of director compensation that does not signal any change in company strategy or financial health.
Positives
- The grant reflects standard director compensation practices, aligning the director's interests with the long-term performance of the company.
Negatives
- None identified.
Risks
- The value of the deferred share units is tied to the future fair market value of Johnson & Johnson common stock at the time of settlement.
Future Outlook
The deferred share units are intended to be settled in cash upon the termination of the director's tenure, with the payout value determined by the share price at that future date.
Management Comments
- The grant is part of the Issuer's Amended and Restated Deferred Fee Plan for Directors.
Industry Context
StockSavvy.ai notes that this is a routine administrative filing regarding director compensation, which is standard practice for large-cap pharmaceutical companies to ensure board alignment with shareholder interests.
Comparison to Industry Standards
- The use of deferred share units for director compensation is a standard governance practice among S&P 500 companies, including peers like Pfizer and Merck.
- The structure of the compensation plan is consistent with typical corporate governance guidelines for major healthcare corporations.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Director Paula A. Johnson authorized specific company and legal personnel to file SEC documents on her behalf. | 2025-12-03 | Administrative update to facilitate regulatory compliance. |
Stakeholder Impact
- Minimal impact on shareholders as this is a standard compensation award.
Next Steps
- No further action required by the reporting person other than future periodic reporting of holdings.
Key Dates
| Date | Description |
|---|---|
| 2025-12-03 | Date of Power of Attorney execution. |
| 2026-04-23 | Date of the reported transaction involving the grant of deferred share units. |
| 2026-04-27 | Date of filing for the Form 4. |
Keywords
Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.